BankPlus Trust Department Purchases Shares of 7,621 Eli Lilly and Company (NYSE:LLY)

BankPlus Trust Department purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, HoldingsChannel reports. The fund purchased 7,621 shares of the company’s stock, valued at approximately $5,883,000. Eli Lilly and Company comprises 1.9% of BankPlus Trust Department’s holdings, making the stock its 6th largest holding.

Several other large investors have also made changes to their positions in the business. AMF Tjanstepension AB raised its position in shares of Eli Lilly and Company by 113.7% during the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after buying an additional 176,552 shares during the last quarter. Values Added Financial LLC lifted its stake in Eli Lilly and Company by 4.9% in the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock worth $324,000 after purchasing an additional 17 shares in the last quarter. Heritage Oak Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 109.8% in the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 860 shares of the company’s stock worth $762,000 after purchasing an additional 450 shares in the last quarter. Hudock Inc. boosted its holdings in shares of Eli Lilly and Company by 0.8% during the 3rd quarter. Hudock Inc. now owns 2,797 shares of the company’s stock valued at $2,478,000 after purchasing an additional 23 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL grew its position in shares of Eli Lilly and Company by 8.3% during the third quarter. Strategic Investment Solutions Inc. IL now owns 676 shares of the company’s stock valued at $599,000 after purchasing an additional 52 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research reports. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Wells Fargo & Company cut their target price on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Finally, Bank of America restated a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Trading Up 0.1 %

NYSE LLY opened at $874.12 on Monday. The stock has a market cap of $828.82 billion, a PE ratio of 74.65, a PEG ratio of 1.40 and a beta of 0.42. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The company’s 50-day moving average price is $801.33 and its 200-day moving average price is $847.66. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its board has approved a stock repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 51.24%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.